Cisplatin or Carboplatin

DRUG16 trials

Sponsors

Fudan University, Robert Ferris, OncoMed Pharmaceuticals, Inc., NovoCure Ltd., Memorial Sloan Kettering Cancer Center

Conditions

Cervical CancerLimited-stage Small Cell Lung Cancer (LS-SCLC)Lung CancerMalignant Pleural MesotheliomaMetastatic NSCLCNSCLC (Advanced Non-small Cell Lung Cancer)Non Small Cell Lung CancerNon-Small Cell Lung Cancer

Phase 1

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

TerminatedNCT01859741

OncoMed Pharmaceuticals, Inc.Stage IV Small Cell Lung Cancer

Start: 2012-01-07End: 2017-05-08Updated: 2020-09-09

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Active, not recruitingNCT04162015

Memorial Sloan Kettering Cancer CenterMalignant Pleural Mesothelioma

Start: 2019-11-12End: 2026-11-30Updated: 2025-09-12

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

RecruitingNCT06839105

Shanghai Junshi Bioscience Co., Ltd.Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

Start: 2025-02-21End: 2028-04-30Target: 214Updated: 2025-05-31

Phase 2

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Fudan UniversityNon-small Cell Lung Cancer, Toxicity

Start: 2009-12-31Target: 68Updated: 2010-09-03

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

CompletedNCT01218048

Robert FerrisSquamous Cell Carcinoma of the Head and Neck

Start: 2011-02-28End: 2017-02-14Updated: 2018-08-16

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

CompletedNCT02397928

NovoCure Ltd.Malignant Pleural Mesothelioma

Start: 2015-02-28End: 2018-04-30Updated: 2018-09-25

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

CompletedNCT04868708

AkesoRecurrent or Metastatic Cervical Cancer

Start: 2021-04-01End: 2024-02-28Updated: 2025-03-04

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Hunan Cancer HospitalCervical Cancer

Start: 2021-05-20End: 2023-05-20Target: 46Updated: 2021-08-10

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Hunan Cancer HospitalCervical Cancer

Start: 2021-12-01End: 2023-12-12Target: 46Updated: 2021-12-09

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

WithdrawnNCT05948462

SCRI Development Innovations, LLCLung Cancer, Non-small Cell Lung Cancer

Start: 2023-11-30End: 2025-09-30Updated: 2023-12-13

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Not yet recruitingNCT06299371

Liaoning Cancer Hospital & InstituteNon Small Cell Lung Cancer

Start: 2024-04-15End: 2029-04-15Target: 36Updated: 2024-03-07

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Active, not recruitingNCT07005336

TJ Biopharma Co., Ltd.Non Small Cell Lung Cancer

Start: 2025-01-09End: 2029-01-09Target: 150Updated: 2026-01-30

Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer

Not yet recruitingNCT07538258

Yayi HeLimited-stage Small Cell Lung Cancer (LS-SCLC)

Start: 2026-04-20End: 2029-03-31Target: 27Updated: 2026-04-20

Phase 3

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

RecruitingNCT06829459

Shanghai JMT-Bio Inc.Non-Small Cell Lung Cancer

Start: 2025-04-03End: 2029-02-15Target: 350Updated: 2025-04-08

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

Not yet recruitingNCT07524257

ImmunityBio, Inc.Metastatic NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2026-05-29End: 2029-12-30Target: 494Updated: 2026-05-04

Phase 4

Incidence of Ototoxicity caused by platinum-based chemotherapy in Thai non-head and Neck irradiated cancerous patients

Active, not recruitingTCTR20130922001

Faculty of Medicine, Khon Kaen UniversityOtotoxicity Sensorineural hearing loss High frequency hearing loss Toxic labyrinthitis

Start: 2013-09-22Target: 82Updated: 2026-04-27

Related Papers

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.

2025-04-23

Abstract 5817: Single cell profiling of diffuse pleural mesothelioma reveals tumor cell plasticity and dynamic immune responses when exposed to platinum, pemetrexed and nivolumab

Cancer Research2025-04-21

Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study.

Journal of Clinical Oncology2024-06-012 citations

Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

Clinical Cancer Research2024-02-1943 citations

Management of tumor treating fields (TTFields) therapy-related skin adverse events in pleural mesothelioma: A single center experience of TTFields therapy concomitant with chemotherapy.

Journal of Clinical Oncology2023-06-011 citations

Abstract 4338: Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit

Cancer Research2023-04-04

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit

Clinical Cancer Research2023-01-039 citations

A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

Journal of Clinical Oncology2022-06-0140 citations

Abstract 1064: Antiproliferative effects of Tumor Treating Fields in human mesothelioma cell lines

Cancer Research2021-07-01

Abstract 573: Efficacy of Tumor Treating Fields (TTFields) in combination with cisplatin or pemetrexed for the treatment of mesothelioma in vitro and in vivo

Cancer Research2020-08-15

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

2019-10-15114 citations

Abstract 688: Safety and efficacy of TTFields delivery to the lungs: A computational study

Cancer Research2019-07-011 citations

Abstract 688: Safety and efficacy of TTFields delivery to the lungs: A computational study

Bioinformatics, Convergence Science, and Systems Biology2019-07-01

Radiological response patterns in the phase 2 STELLAR trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2019-05-203 citations

Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields.

Journal of Clinical Oncology2019-05-20

Safety meta-analysis of clinical trials delivering TTFields to the upper torso

Annals of Oncology2019-04-01

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.

2018-12-2859 citations

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).

2018-02-0727 citations

Abstract 4528: A novel transducer array design optimizing TTFields delivery to the thorax

Cancer Research2017-07-01

Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome

Cancer Research2017-07-01

5 more papers not shown